Jared Kaltwasser

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

Physicians should proactively ask patients what alternative therapies, if any, they are using.

In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.

However, Clostridioides difficile (CDI) infection did not appear to affect outcomes, according to the study.

Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

Although acne and rosacea treatment are widely covered, treatment for other types of skin conditions are not covered at all, a new report shows.

Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

Investigators said disease-modifying therapies may change the treatment landscape of sickle cell disease (SCD).

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

Focus groups show patients who have sickle cell disease (SCD) like the idea of a digital health app for cognitive behavioral therapy (CBT) that allows them to make meaningful connections with people with shared experiences.

Even after adjusting for other risk factors, patients with COPD were more likely to be readmitted to the hospital with heart failure following an acute myocardial infarction, or heart attack.

Health systems participating in the drug discount program did not have fewer disparities than hospitals not participating.

The patient had hemophilia A, but reported no trauma preceding the hematoma.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

Just 29% of patients listed a treatment-response goal among their top personal goals.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The results of a new focus group offer insights on how and when people with rare diseases are willing to share their personal health information.

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

Treatment options have improved care, but also increased the need for patient education.

About a quarter of joints examined had at least 1 joint bleed.

Investigators said data show social factors are intertwined with health outcomes.

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.

However, the patients also said they worried about insufficient care coordination between specialists and other care providers.

Investigators found patients with acute coronary syndrome were 3 times more likely to die in the hospital.

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).